Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma : a comparative retrospective study from the InspECT and Slovenian Cancer Registry
Authors:ID Campana, Luca Giovanni (Author)
ID Perić, Barbara (Author)
ID Mascherini, Matteo (Author)
ID Spina, Romina (Author)
ID Kunte, Christian (Author)
ID Kis, Erika (Author)
ID Rozsa, Petra (Author)
ID Quaglino, Pietro (Author)
ID Čemažar, Maja (Author)
ID Omerzel, Maša (Author)
ID Serša, Gregor (Author)
Files:URL URL - Source URL, visit https://www.mdpi.com/2072-6694/13/17/4289
 
.pdf PDF - Presentation file, download (701,05 KB)
MD5: F2DD7681624B085555665A4B6B6F5059
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:Electrochemotherapy (ECT) is an effective locoregional therapy for cutaneous melanoma metastases and has been safely combined with immune checkpoint inhibitors in preliminary experiences. Since ECT is known to induce immunogenic cell death, its combination with immune checkpoint inhibitors might be beneficial. In this study, we aimed to investigate the effectiveness of ECT on cutaneous melanoma metastases in combination with pembrolizumab. We undertook a retrospective matched cohort analysis of stage IIIC%IV melanoma patients, included in the International Network for sharing practices of ECT (InspECT) and the Slovenian Cancer Registry. We compared the outcome of patients who received the following treatments: (a) pembrolizumab alone, (b) pembrolizumab plus ECT, and (c) ECT. The groups were matched for age, sex, performance status, and size of skin metastases. The local objective response rate (ORR) was higher in the pembrolizumab-ECT group than in the pembrolizumab group (78% and 39%, p < 0.001). The 1 year local progression-free survival (LPFS) rates were 86% and 51% (p < 0.001), and the 1 year systemic PFS rates were 64% and 39%, respectively (p = 0.034). The 1 year overall survival (OS) rates were 88% and 64%, respectively (p = 0.006). Our results suggest that skin-directed therapy with ECT improves superficial tumor control in melanoma patients treated with pembrolizumab. Interestingly, we observed longer PFS and OS in the pembrolizumab-ECT group than in the pembrolizumab group. These findings warrant prospective confirmation.
Keywords:electrochemotherapy, metastatic melanoma, skin metastases
Publication status:Published
Publication version:Version of Record
Publication date:25.08.2021
Publisher:MDPI
Year of publishing:2021
Number of pages:str. 4289-1-4289-13
Numbering:Vol. 13, no. 17
PID:20.500.12556/DiRROS-15616 New window
UDC:616.5
ISSN on article:2072-6694
DOI:10.3390/cancers13174289 New window
COBISS.SI-ID:74755075 New window
Copyright:by Authors
Note:Nasl. z nasl. zaslona; Opis vira z dne 31. 8. 2021;
Publication date in DiRROS:10.10.2022
Views:978
Downloads:550
Metadata:XML DC-XML DC-RDF
:
CAMPANA, Luca Giovanni, PERIĆ, Barbara, MASCHERINI, Matteo, SPINA, Romina, KUNTE, Christian, KIS, Erika, ROZSA, Petra, QUAGLINO, Pietro, ČEMAŽAR, Maja, OMERZEL, Maša and SERŠA, Gregor, 2021, Combination of pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma : a comparative retrospective study from the InspECT and Slovenian Cancer Registry. Cancers [online]. 2021. Vol. 13, no. 17, p. 4289-1-4289–13. [Accessed 15 March 2025]. DOI 10.3390/cancers13174289. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=15616
Copy citation
  
Share:Bookmark and Share


Searching for similar works...Please wait....
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 New window

Document is financed by a project

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003-2015
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:08.10.2022

Secondary language

Language:Slovenian
Keywords:elektrokemoterapija, metastatski melanom, kožne metastaze


Back